Fast Facts About GI Alliance
The company is also the most geographically dispersed gastroenterology organization in the U.S., according to a report jointly published by consulting firm Fraser Healthcare and pharma research firm Spherix Global Insights. Despite its size, the company remains physician-led and majority physician-owned.
Mayzent and Kesimpta Gaining Ground as MS Treatments in Canada
Novartis’ Mayzent (siponimod) and Kesimpta (ofatumumab) are gaining ground among multiple sclerosis (MS) therapies in Canada, according to the latest Spherix Global Insights’ report. “Following an eventful 2021 that included the launch of two new brands — Novartis’ Kesimpta and BMS’ Zeposia — and generic versions of Biogen’s Tecfidera, the Canadian multiple sclerosis (MS) market appears to be settling into patterns […]
Betting on ‘Golden Age’ of Colonoscopies, Investors Buy Up Gastroenterology Practices
In 2021, the number of private equity acquisitions of gastroenterology practices grew by 28% over the previous year, according to Spherix Global Insights and Fraser Healthcare. Complex government regulations, technological innovations, and insurance industry practices have driven many gastroenterologists to sell shares in their practices, said Praveen Suthrum, who runs a consulting company for physician […]
Novartis’ Multiple Sclerosis Brands Mayzent and Kesimpta Both Show Strong Growth in Canada
Despite a negative CDEC1 reimbursement recommendation, BMS’ Zeposia has seen notable growth in the past six months, with neurologists optimistic about the future EXTON, Pa., May 26, 2022/PRNewswire – Following an eventful 2021 that included the launch of two new brands—Novartis’ Kesimpta and BMS’ Zeposia—and generic versions of Biogen’s Tecfidera, the Canadian multiple sclerosis (MS) […]
As New C. Diff Treatments Prep for Market, Specialists Divided on ‘Poop in a Pill’ or Small Molecule, Study Finds
What do physicians think about the emerging market for recurrent C. diff? That depends on who you talk to, especially which specialists you talk to. Fecal microbiota transplants, or FMT, are favored by gastroenterologists…
Neurologists’ React to CMS’ Finalized NCD Decision on Anti-Amyloid Monoclonal Antibodies for Alzheimer’s Disease
Spherix captures potential impact on Eisai/Biogen’s lecanemab, Eli Lilly’s donanemab, and Roche/Genentech’s gantenerumab EXTON, Pa., / May 16, 2022 / 6PRNewswire – On April 7, 2022, CMS finalized its NCD for anti-amyloid monoclonal antibodies (mAbs) for the treatment of Alzheimer’s disease. Given the importance of this decision on the burgeoning treatment landscape, Spherix surveyed 81 […]
Roche’s Susvimo Has its Advantages, but Eye Doctors are Sticking with Eylea
Roche’s new eye drug delivery therapy Susvimo is becoming well known among eye doctors, but it has a major battle on its hands to shift market share away from the major blockbuster that is Regeneron and Bayer’s Eylea. This is according to a new report from Spherix analysts, based on conversations with 76 ophthalmologists in […]
Eylea Keeps its Lead In the Retinal Space as Physicians Remain Hesitant on Roche’s Susvimo — Report
Roche trumpeted a “major advancement” in the retinal space with the approval of its eye drug Susvimo last October, touting it as a more manageable option for patients with wet age-related macular degeneration. However, safety concerns leave some physicians hesitant. While most ophthalmologists have heard of Susvimo — 86%, according to the latest Spherix survey […]
Spherix Global Insights Identifies Significant Unmet Need and Strong Opportunity for a Newly Launched Mechanism of Action in IBS-C Market
Market entry of Ardelyx’s Ibsrela has potential to disrupt the treatment landscape EXTON, Pa., May 12, 2022 /PRNewswire/ — Spherix recently surveyed 102 gastroenterologists and 100 primary care physicians (PCPs), including eight qualitative interviews with gastroenterologists, to gain perspective on the current and future management of irritable bowel syndrome with constipation (IBS-C). Data captured in […]
RA Patients in Great Need of New Treatment Options
Almost half, 49 percent, of rheumatologists, decreased prescriptions of Xeljanz over the past three months, according to Spherix Global Insights’ report for the first quarter. The decline in the prescription of Rinvoq and Olumiant was not as big during the period – just under 25 percent of rheumatologists reduced their use of these JAK inhibitors…
